Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7149090 | 1.00 | LMNA (0.31) | LMNATSHRMEN1ALDH1A1CYP3A4 | |
| SCHEMBL29070637 | 0.85 | — | — | |
| SCHEMBL30198804 | 0.74 | MEN1 (0.33) | MEN1ALDH1A1CYP3A4KMT2A | |
| SCHEMBL10738039 | 0.74 | MEN1 (0.36) | MEN1ALDH1A1CYP3A4KMT2A | |
| SCHEMBL2543405 | 0.74 | MEN1 (0.36) | MEN1ALDH1A1CYP3A4KMT2A | |
| SCHEMBL4959097 | 0.73 | — | — | |
| SCHEMBL9053292 | 0.68 | MEN1 (0.32) | MEN1ALDH1A1CYP3A4KMT2A | |
| SCHEMBL9052184 | 0.68 | MEN1 (0.32) | MEN1ALDH1A1CYP3A4KMT2A | |
| SCHEMBL368962 | 0.67 | — | — | |
| SCHEMBL15533578 | 0.67 | MEN1 (0.30) | MEN1ALDH1A1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608350-A1 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | Ellipsis Biotherapeutics Corporation (CA) | 2005-12-28 | — | — | EP | claimed |
| US-20040204387-A1 | administering to subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof; for treating or preventing condition of central or peripheral nervous system or systemic organ associated with a disorder in protein folding or aggregation, or amyloid formation | MCLAURIN JOANNE (CA) | 2004-10-14 | — | — | US | claimed |
| WO-2004075882-A1 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | ELLIPSIS BIOTHERAPEUTICS CORPORATION (CA) | 2004-09-10 | — | — | WO | claimed |
| EP-1151125-A4 | BIOCATALYTIC SYNTHESIS OF QUINIC ACID AND CONVERSION TO HYDROQUINONE | UNIV MICHIGAN STATE (US) | 2003-04-23 | — | — | EP | claimed |
| US-20020142409-A1 | Biocatalytic synthesis of quinic acid and conversion to hydroquinone | NATIONAL SCIENCE FOUNDATION | 2002-10-03 | — | — | US | claimed |
| EP-1151125-A1 | BIOCATALYTIC SYNTHESIS OF QUINIC ACID AND CONVERSION TO HYDROQUINONE | Board of Trustees operating Michigan State University (US) | 2001-11-07 | — | — | EP | claimed |
| WO-2000044924-A1 | BIOCATALYTIC SYNTHESIS OF QUINIC ACID AND CONVERSION TO HYDROQUINONE | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 2000-08-03 | — | — | WO | claimed |
| US-9833420-B2 | Methods of preventing, treating, and diagnosing disorders of protein aggregation | MCLAURIN JOANNE (CA) | 2017-12-05 | — | — | US | disclosed |
| US-20150164821-A1 | METHODS OF PREVENTING, TREATING, AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | MCLAURIN JOANNE (CA) | 2015-06-18 | — | — | US | disclosed |
| US-20150031776-A1 | METHOD OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | MCLAURIN JOANNE (CA) | 2015-01-29 | — | — | US | disclosed |
| EP-2823813-A1 | Methods of preventing, treating and diagnosing disorders of protein aggregation | McLaurin, Joanne (CA) | 2015-01-14 | — | — | EP | disclosed |
| US-8859628-B2 | Method for preventing, treating and diagnosing disorders of protein aggregation | MCLAURIN JOANNE (CA) | 2014-10-14 | — | — | US | disclosed |
| US-20140073701-A1 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | MCLAURIN JOANNE (CA) | 2014-03-13 | — | — | US | disclosed |
| US-20030203460-A1 | Biocatalytic synthesis of quinic acid and conversion to hydroquinone | NATIONAL SCIENCE FOUNDATION | 2003-10-30 | — | — | US | disclosed |
| US-6620602-B2 | Generation of hydroquinone and derivatives; obtain quinic acid, oxidize to 3,4,5-trihydroxycyclohexanone, convert 3,4,5-trihydroxycyclohexanone to hydroquinone | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY | 2003-09-16 | — | — | US | disclosed |
| US-6600077-B1 | Biocatalytic synthesis of quinic acid and conversion to hydroquinone | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY | 2003-07-29 | — | — | US | disclosed |
| EP-1151125-A4 | BIOCATALYTIC SYNTHESIS OF QUINIC ACID AND CONVERSION TO HYDROQUINONE | UNIV MICHIGAN STATE (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020142409-A1 | Biocatalytic synthesis of quinic acid and conversion to hydroquinone | NATIONAL SCIENCE FOUNDATION | 2002-10-03 | — | — | US | disclosed |
| EP-1151125-A1 | BIOCATALYTIC SYNTHESIS OF QUINIC ACID AND CONVERSION TO HYDROQUINONE | Board of Trustees operating Michigan State University (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000044924-A1 | BIOCATALYTIC SYNTHESIS OF QUINIC ACID AND CONVERSION TO HYDROQUINONE | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204387-A1 | administering to subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof; for treating or preventing condition of central or peripheral nervous system or systemic organ associated with a disorder in protein folding or aggregation, or amyloid formation | IAPP, PLPBP, PPIP5K2 | LMNA 1507/4885TSHR 2748/4885MEN1 842/4885 |
| US-20150164821-A1 | METHODS OF PREVENTING, TREATING, AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | TTR, APP, IAPP | LMNA 499/4885TSHR 3386/4885MEN1 1751/4885 |
| US-20150031776-A1 | METHOD OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | TTR, IAPP, APP | LMNA 561/4885TSHR 3315/4885MEN1 1553/4885 |
| US-20140073701-A1 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | TTR, IAPP, PRNP | LMNA 496/4885TSHR 3399/4885MEN1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.